Glucagon and Oxyntomodulin

Evaluation of Linearity, Lower Limit of Measurement Interval and Imprecision
  • Organism: Homo sapiens
  • Instrument: Xevo TQ-S
  • SpikeIn: No
  • Keywords: glucagon, oxyntomodulin, single point calibration, primary calibrator
  • Lab head: Andy Hoofnagle Submitter: Jess Becker
Abstract
Introduction Glucagon and oxyntomodulin are peptide hormones differentially released from proglucagon that function in regulating blood glucose concentrations. Their overlapping amino acid sequences make the development of specific immunoassays difficult, but the specificity of liquid chromatography-tandem mass spectrometry can be used to distinguish the peptides. We aimed to develop a sensitive and specific mass spectrometric assay that uses non-proprietary reagents and normal-flow liquid chromatography in the simultaneous quantification of both analytes. Methods Bulk plasma proteins were precipitated in ethanol/ammonium hydroxide. Analytes were enriched using monoclonal antibodies generated in-house and analyzed using liquid chromatography-tandem mass spectrometry. A purified primary glucagon calibration material was sourced commercially and characterized for purity and concentration by HPLC-UV and amino acid analysis. Single point calibration was used to minimize between-day variability. Results The novel antibodies performed acceptably (peptide recovery 45-59%). The assay was precise (<13 %CV) and linear over the range of 1.3-14.7 pM and 1.1-13.7 pM for glucagon and oxyntomodulin, respectively. The primary calibrator concentration was determined to be 1.596 mg/g. Tube-type studies supported the use of protease inhibitor tubes at the time of blood draw. Patients with type 1 diabetes had lower concentrations of plasma glucagon when maintained on an insulin pump, but not with injectable insulin. Conclusion We have validated a method with a highly detailed standard operating procedure. We have characterized a reference material to help maintain accuracy and achieve between-assay and between-laboratory harmonization. The assay will be beneficial in better understanding α-cell health and glycemic control in diabetes and other diseases.
Created on 4/7/23, 11:19 AM
The attached Excel file identifies the samples in the uploaded Skyline files.

  Attached Files  
   
 241118_Validation_Files_Key_For_Panorama.xlsx

Clustergrammer Heatmap
 
Download
220910_PreAnalyticalStability.sky.zip2024-11-18 15:32:27313515454
220907_2Week_Stability.sky.zip2024-11-18 15:32:26313515274
220829_Stability_Extracted4CvialsON_minus80_4days.sky.zip2024-11-18 15:32:25313515174
220826_Time2_SampleStability.sky.zip2024-11-18 15:32:24313515374
220825_Time0_SampleStability.sky.zip2024-11-18 15:32:23313515174
220825_Time1_SampleStability.sky.zip2024-11-18 15:32:22313515174
240226_GluOx_InterferenceSet6_Ext9Feb.sky.zip2024-11-18 15:08:30313515494
240225_GluOx_InterferenceSet5_Ext8Feb.sky.zip2024-11-18 15:08:29313515464
240205_Interference_Set4_Ext18Dec.sky.zip2024-11-18 15:08:28313515404
231221_InterferenceSet3_ExtDec17.sky.zip2024-11-18 15:08:27313515394
231217_Interference_Set2_ExtractedDec11.sky.zip2024-11-18 15:08:26313515384
231211_Interference_Set1_Complete.sky.zip2024-11-18 15:08:26313515394
220909_PlasmaVsSerum.sky.zip2024-11-18 14:20:15313515344
220822_5x5d6_nLLMId3_2023-04-07_13-17-19.sky.zip2023-04-07 13:17:33425927387
220825_Linearity_2023-04-07_13-14-24.sky.zip2023-04-07 13:14:26313515324
220731_BasePrecip_IA_5x5nLLMI_day5_2023-04-06_16-42-06.sky.zip2023-04-06 16:42:12425927347
220805_5x5_Day4_2023-04-06_16-41-23.sky.zip2023-04-06 16:41:31425927377
220731_BasePrecip_IA_5x5nLLMI_day3_2023-04-06_16-40-39.sky.zip2023-04-06 16:40:47425927397
220727_BasePrecip_IA_5x5nLLMI_Day2_2023-04-06_16-39-52.sky.zip2023-04-06 16:39:59425927347
220724_BasePrecip_IA_5x5nLLMI_day1_2023-04-06_16-38-36.sky.zip2023-04-06 16:38:48425927347
2200908_Linearity_Try2_2023-04-06_16-37-03.sky.zip2023-04-06 16:37:11313515324